Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.

Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.

BACKGROUND: Campath 1H is a depleting, humanized anti-CD52 monoclonal antibody that has now been used in 31 renal allograft recipients. The results have been very encouraging and are presented herein. METHODS: Campath 1H was administered, intravenously, in a dose of 20 mg, on day 0 and day 1 after...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Calne, R, Moffatt, S, Friend, P, Jamieson, N, Bradley, J, Hale, G, Firth, J, Smith, K, Waldmann, H
Format:	Journal article
Język:	English
Wydane:	1999

Podobne zapisy

Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.
od: Calne, R, i wsp.
Wydane: (1998)

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
od: Watson, C, i wsp.
Wydane: (2005)

Reversal of allograft rejection using the monoclonal antibody, Campath-1G.
od: Friend, P, i wsp.
Wydane: (1991)

CAMPATH-IH in multiple sclerosis.
od: Moreau, T, i wsp.
Wydane: (1996)

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
od: Watson, C, i wsp.
Wydane: (2004)

Delayed allograft rejection in primates treated with anti-IL-2 receptor monoclonal antibody Campath-6.
od: Tighe, H, i wsp.
Wydane: (1988)

Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation.
od: Hale, G, i wsp.
Wydane: (1986)

CAMPATH-1 FOLLOWING RENAL-TRANSPLANTATION - A RANDOMIZED TRIAL
od: Friend, P, i wsp.
Wydane: (1988)

Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
od: Naparstek, E, i wsp.
Wydane: (1999)

Campath-1M--prophylactic use after kidney transplantation. A randomized controlled clinical trial.
od: Friend, P, i wsp.
Wydane: (1989)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
od: Clatworthy, MR, i wsp.
Wydane: (2009)

CAMPATH: from concept to clinic.
od: Waldmann, H, i wsp.
Wydane: (2005)

Specificity of monoclonal antibody Campath-1.
od: Hale, G, i wsp.
Wydane: (1988)

CAMPATH-1H in inflammatory arthritis.
od: Watts, R, i wsp.
Wydane: (1993)

T-cell depletion of stem cell grafts with campath-1H "in the bag" followed by cyclosporin immunosuppression remains a cost effective strategy in transplantation
od: Novitzky, N, i wsp.
Wydane: (2004)

Availability of Campath-1 antibodies for bone marrow transplantation.
od: Hale, G, i wsp.
Wydane: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
od: Hale, G, i wsp.
Wydane: (1994)

CAMPATH-1H for the treatment of acute rejection in kidney transplant recipients: 10 year follow-up
od: Clatworthy, MR, i wsp.
Wydane: (2007)

Addition of cyclosporin post transplantation decreases GvHD without enhancing the adverse effect of T-cell depletion with CAMPATH-1H "in the bag": The cape town experience
od: Novitzky, N, i wsp.
Wydane: (2003)

The CAMPATH-1 antigen (CDw52).
od: Hale, G, i wsp.
Wydane: (1990)

Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection.
od: Rebello, P, i wsp.
Wydane: (1999)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
od: Hale, G, i wsp.
Wydane: (1988)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
od: Hale, G, i wsp.
Wydane: (1996)

Campath-1H therapy in refractory ocular inflammatory disease.
od: Dick, A, i wsp.
Wydane: (2000)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
od: Watts, R, i wsp.
Wydane: (1992)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
od: Waldmann, H, i wsp.
Wydane: (1987)

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
od: Isaacs, J, i wsp.
Wydane: (1996)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
od: Hale, G, i wsp.
Wydane: (2002)

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
od: Killick, S, i wsp.
Wydane: (1997)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
od: Williams, R, i wsp.
Wydane: (2000)

Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody.
od: Friend, P, i wsp.
Wydane: (1995)

CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP)
od: Lim, S, i wsp.
Wydane: (1993)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
od: Novitzky, N, i wsp.
Wydane: (2004)

CAMPATH-1 antibodies in stem-cell transplantation.
od: Hale, G, i wsp.
Wydane: (2001)

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen.
od: Xia, M, i wsp.
Wydane: (1993)

COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
od: Fibbe, W, i wsp.
Wydane: (1993)

Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series.
od: Waldmann, H, i wsp.
Wydane: (1985)

EFFECTS OF MONOCLONAL-ANTIBODIES OF THE CAMPATH SERIES INVIVO - REQUIREMENTS FOR EFFECTIVE ANTIBODY THERAPY
od: Dyer, M, i wsp.
Wydane: (1988)

CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
od: Lim, S, i wsp.
Wydane: (1993)

ISOTYPE VARIANTS OF CAMPATH-1 ANTIBODY - REQUIREMENTS FOR EFFECTIVE ANTIBODY ACTION INVIVO
od: Dyer, M, i wsp.
Wydane: (1989)